These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 219650)

  • 1. Metabolic effects of glucagon in endogenous hypertriglyceridemia.
    Nosadini R; Soldà G; de Biasi F; Tiengo A
    Acta Diabetol Lat; 1978; 15(5-6):251-8. PubMed ID: 219650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
    Tiengo A; Muggeo M; Assan R; Fedele D; Crepaldi G
    Metabolism; 1975 Aug; 24(8):901-14. PubMed ID: 1143089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of fatty acid metabolism by glucagon in man. II. Effects in insulin-deficient diabetics.
    Schade DS; Eaton RP
    Diabetes; 1975 May; 24(5):510-5. PubMed ID: 805077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon on plasma lipids in different types of primary hyperlipoproteinemia.
    Aubry F; Marcel YL; Davignon J
    Metabolism; 1974 Mar; 23(3):225-38. PubMed ID: 4813955
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucagon and lipoproteins.
    Eaton RP
    Metabolism; 1976 Nov; 25(11 Suppl 1):1415-7. PubMed ID: 790087
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulsatile glucagon has greater hyperglycaemic, lipolytic and ketogenic effects than continuous hormone delivery in man: effect of age.
    Paolisso G; Buonocore S; Gentile S; Sgambato S; Varricchio M; Scheen A; D'Onofrio F; Lefèbvre PJ
    Diabetologia; 1990 May; 33(5):272-7. PubMed ID: 2198186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans.
    Berk MA; Clutter WE; Skor D; Shah SD; Gingerich RP; Parvin CA; Cryer PE
    J Clin Invest; 1985 Jun; 75(6):1842-51. PubMed ID: 3891786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fatty acids on glucose production and utilization in man.
    Ferrannini E; Barrett EJ; Bevilacqua S; DeFronzo RA
    J Clin Invest; 1983 Nov; 72(5):1737-47. PubMed ID: 6138367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous glucagon regulation in genetically hyperlipemic obese rats.
    Eaton RP; Conway M; Schade DS
    Am J Physiol; 1976 May; 230(5):1336-41. PubMed ID: 1275076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
    Gerich JE; Lorenzi M; Bier DM; Tsalikian E; Schneider V; Karam JH; Forsham PH
    J Clin Invest; 1976 Apr; 57(4):875-84. PubMed ID: 820717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
    Oakes ND; Thalén PG; Jacinto SM; Ljung B
    Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypolipemic glucagon activity in isolated liver of genetic or acquired hypertriglyceridemic rats.
    Nosadini R; Meneghel A; Del Prato S; Fedele D; Tiengo A
    Diabete Metab; 1980 Jun; 6(2):129-33. PubMed ID: 7409295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic effects of graded glucagon infusions in man: inhibition of glucagon, insulin, and somatostatin response to arginine.
    Pontiroli AE; Perfetti MG; Andreotti AC; Fattor B; Monti LD; Pozza G
    Metabolism; 1993 Oct; 42(10):1242-8. PubMed ID: 8105365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the catabolic activity of glucagon by endogenous insulin secretion in obese man.
    Schade DS; Eaton PR
    Acta Diabetol Lat; 1977; 14(1-2):62-72. PubMed ID: 596102
    [No Abstract]   [Full Text] [Related]  

  • 15. Ketogenic action of glucagon in insulin-dependent diabetic subjects.
    Harano Y; Ohgaku S; Shimizu Y; Izumi K; Takahashi J
    Endocrinol Jpn; 1977 Apr; 24(2):121-8. PubMed ID: 406133
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulation of fatty acid metabolism by glucagon in man. I. Effects in normal subjects.
    Schade DS; Eaton RP
    Diabetes; 1975 May; 24(5):502-9. PubMed ID: 1126591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis.
    Schlierf G; Dorow E
    J Clin Invest; 1973 Mar; 52(3):732-40. PubMed ID: 4685092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and action in hypertriglyceridemia.
    Zuniga-Guarjardo S; Steiner G; Shumak S; Zinman B
    Diabetes Res Clin Pract; 1991 Oct; 14(1):55-61. PubMed ID: 1748063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the adrenal glands in insulin-induced free fatty acid mobilization in the chicken.
    Veiga JA; Linder C; Moura JL
    Braz J Med Biol Res; 1983 Dec; 16(4):375-80. PubMed ID: 6370355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of endogenous insulin secretion to the ketogenic response to glucagon in man.
    Schade DS; Eaton RP
    Diabetologia; 1975 Dec; 11(6):555-9. PubMed ID: 1205024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.